Evidence map›Paper›PMID 26678453›Full record

ArticleRadiology2016

Multimodality Imaging of Ethiodized Oil-loaded Radiopaque Microspheres during Transarterial Embolization of Rabbits with VX2 Liver Tumors.

Vania Tacher, Rafael Duran, MingDe Lin, Jae Ho Sohn, Karun V Sharma, Zhijun Wang, Julius Chapiro, Carmen Gacchina Johnson, Nikhil Bhagat, Matthew R Dreher and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Radiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Review
  2. Review
  3. Application of Nanotechnology in TACE Treatment of Liver Cancer.International journal of nanomedicine · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Theranostics · 2018
    Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Vania TacherFrom the Russell H. Morgan Department of Radiology and Radiological Science, Division of Vascular and Interventional Radiology, Johns Hopkins Hospital, Baltimore, Md (V.T., R.D., J.H.S., Z.W., J.C., N.B., J.F.G.); Department of Radiology, Yale University School of Medicine, 330 Cedar St, TE 2-230, New Haven, CT 06520 (R.D., J.H.S., J.C., J.F.G.); U/S Imaging and Interventions (UII), Philips Research North America, Cambridge, Mass (M.L.); Center for Interventional Oncology, Interventional Radiology Section, National Institutes of Health, Bethesda, Md (K.V.S., C.G.J., M.R.D., D.L.W., B.J.W.); Biocompatibles UK Ltd, Farnham, Surrey, England (M.R.D., A.L.L., Y.T.); and Philips Research Hamburg, Hamburg, Germany (D.S., M.G.).
Rafael DuranFrom the Russell H. Morgan Department of Radiology and Radiological Science, Division of Vascular and Interventional Radiology, Johns Hopkins Hospital, Baltimore, Md (V.T., R.D., J.H.S., Z.W., J.C., N.B., J.F.G.); Department of Radiology, Yale University School of Medicine, 330 Cedar St, TE 2-230, New Haven, CT 06520 (R.D., J.H.S., J.C., J.F.G.); U/S Imaging and Interventions (UII), Philips Research North America, Cambridge, Mass (M.L.); Center for Interventional Oncology, Interventional Radiology Section, National Institutes of Health, Bethesda, Md (K.V.S., C.G.J., M.R.D., D.L.W., B.J.W.); Biocompatibles UK Ltd, Farnham, Surrey, England (M.R.D., A.L.L., Y.T.); and Philips Research Hamburg, Hamburg, Germany (D.S., M.G.).
MingDe LinFrom the Russell H. Morgan Department of Radiology and Radiological Science, Division of Vascular and Interventional Radiology, Johns Hopkins Hospital, Baltimore, Md (V.T., R.D., J.H.S., Z.W., J.C., N.B., J.F.G.); Department of Radiology, Yale University School of Medicine, 330 Cedar St, TE 2-230, New Haven, CT 06520 (R.D., J.H.S., J.C., J.F.G.); U/S Imaging and Interventions (UII), Philips Research North America, Cambridge, Mass (M.L.); Center for Interventional Oncology, Interventional Radiology Section, National Institutes of Health, Bethesda, Md (K.V.S., C.G.J., M.R.D., D.L.W., B.J.W.); Biocompatibles UK Ltd, Farnham, Surrey, England (M.R.D., A.L.L., Y.T.); and Philips Research Hamburg, Hamburg, Germany (D.S., M.G.).
Jae Ho SohnFrom the Russell H. Morgan Department of Radiology and Radiological Science, Division of Vascular and Interventional Radiology, Johns Hopkins Hospital, Baltimore, Md (V.T., R.D., J.H.S., Z.W., J.C., N.B., J.F.G.); Department of Radiology, Yale University School of Medicine, 330 Cedar St, TE 2-230, New Haven, CT 06520 (R.D., J.H.S., J.C., J.F.G.); U/S Imaging and Interventions (UII), Philips Research North America, Cambridge, Mass (M.L.); Center for Interventional Oncology, Interventional Radiology Section, National Institutes of Health, Bethesda, Md (K.V.S., C.G.J., M.R.D., D.L.W., B.J.W.); Biocompatibles UK Ltd, Farnham, Surrey, England (M.R.D., A.L.L., Y.T.); and Philips Research Hamburg, Hamburg, Germany (D.S., M.G.).
Karun V SharmaFrom the Russell H. Morgan Department of Radiology and Radiological Science, Division of Vascular and Interventional Radiology, Johns Hopkins Hospital, Baltimore, Md (V.T., R.D., J.H.S., Z.W., J.C., N.B., J.F.G.); Department of Radiology, Yale University School of Medicine, 330 Cedar St, TE 2-230, New Haven, CT 06520 (R.D., J.H.S., J.C., J.F.G.); U/S Imaging and Interventions (UII), Philips Research North America, Cambridge, Mass (M.L.); Center for Interventional Oncology, Interventional Radiology Section, National Institutes of Health, Bethesda, Md (K.V.S., C.G.J., M.R.D., D.L.W., B.J.W.); Biocompatibles UK Ltd, Farnham, Surrey, England (M.R.D., A.L.L., Y.T.); and Philips Research Hamburg, Hamburg, Germany (D.S., M.G.).
Zhijun WangFrom the Russell H. Morgan Department of Radiology and Radiological Science, Division of Vascular and Interventional Radiology, Johns Hopkins Hospital, Baltimore, Md (V.T., R.D., J.H.S., Z.W., J.C., N.B., J.F.G.); Department of Radiology, Yale University School of Medicine, 330 Cedar St, TE 2-230, New Haven, CT 06520 (R.D., J.H.S., J.C., J.F.G.); U/S Imaging and Interventions (UII), Philips Research North America, Cambridge, Mass (M.L.); Center for Interventional Oncology, Interventional Radiology Section, National Institutes of Health, Bethesda, Md (K.V.S., C.G.J., M.R.D., D.L.W., B.J.W.); Biocompatibles UK Ltd, Farnham, Surrey, England (M.R.D., A.L.L., Y.T.); and Philips Research Hamburg, Hamburg, Germany (D.S., M.G.).
Julius ChapiroFrom the Russell H. Morgan Department of Radiology and Radiological Science, Division of Vascular and Interventional Radiology, Johns Hopkins Hospital, Baltimore, Md (V.T., R.D., J.H.S., Z.W., J.C., N.B., J.F.G.); Department of Radiology, Yale University School of Medicine, 330 Cedar St, TE 2-230, New Haven, CT 06520 (R.D., J.H.S., J.C., J.F.G.); U/S Imaging and Interventions (UII), Philips Research North America, Cambridge, Mass (M.L.); Center for Interventional Oncology, Interventional Radiology Section, National Institutes of Health, Bethesda, Md (K.V.S., C.G.J., M.R.D., D.L.W., B.J.W.); Biocompatibles UK Ltd, Farnham, Surrey, England (M.R.D., A.L.L., Y.T.); and Philips Research Hamburg, Hamburg, Germany (D.S., M.G.).
Carmen Gacchina JohnsonFrom the Russell H. Morgan Department of Radiology and Radiological Science, Division of Vascular and Interventional Radiology, Johns Hopkins Hospital, Baltimore, Md (V.T., R.D., J.H.S., Z.W., J.C., N.B., J.F.G.); Department of Radiology, Yale University School of Medicine, 330 Cedar St, TE 2-230, New Haven, CT 06520 (R.D., J.H.S., J.C., J.F.G.); U/S Imaging and Interventions (UII), Philips Research North America, Cambridge, Mass (M.L.); Center for Interventional Oncology, Interventional Radiology Section, National Institutes of Health, Bethesda, Md (K.V.S., C.G.J., M.R.D., D.L.W., B.J.W.); Biocompatibles UK Ltd, Farnham, Surrey, England (M.R.D., A.L.L., Y.T.); and Philips Research Hamburg, Hamburg, Germany (D.S., M.G.).
Nikhil BhagatFrom the Russell H. Morgan Department of Radiology and Radiological Science, Division of Vascular and Interventional Radiology, Johns Hopkins Hospital, Baltimore, Md (V.T., R.D., J.H.S., Z.W., J.C., N.B., J.F.G.); Department of Radiology, Yale University School of Medicine, 330 Cedar St, TE 2-230, New Haven, CT 06520 (R.D., J.H.S., J.C., J.F.G.); U/S Imaging and Interventions (UII), Philips Research North America, Cambridge, Mass (M.L.); Center for Interventional Oncology, Interventional Radiology Section, National Institutes of Health, Bethesda, Md (K.V.S., C.G.J., M.R.D., D.L.W., B.J.W.); Biocompatibles UK Ltd, Farnham, Surrey, England (M.R.D., A.L.L., Y.T.); and Philips Research Hamburg, Hamburg, Germany (D.S., M.G.).
Matthew R DreherFrom the Russell H. Morgan Department of Radiology and Radiological Science, Division of Vascular and Interventional Radiology, Johns Hopkins Hospital, Baltimore, Md (V.T., R.D., J.H.S., Z.W., J.C., N.B., J.F.G.); Department of Radiology, Yale University School of Medicine, 330 Cedar St, TE 2-230, New Haven, CT 06520 (R.D., J.H.S., J.C., J.F.G.); U/S Imaging and Interventions (UII), Philips Research North America, Cambridge, Mass (M.L.); Center for Interventional Oncology, Interventional Radiology Section, National Institutes of Health, Bethesda, Md (K.V.S., C.G.J., M.R.D., D.L.W., B.J.W.); Biocompatibles UK Ltd, Farnham, Surrey, England (M.R.D., A.L.L., Y.T.); and Philips Research Hamburg, Hamburg, Germany (D.S., M.G.).
Dirk SchäferFrom the Russell H. Morgan Department of Radiology and Radiological Science, Division of Vascular and Interventional Radiology, Johns Hopkins Hospital, Baltimore, Md (V.T., R.D., J.H.S., Z.W., J.C., N.B., J.F.G.); Department of Radiology, Yale University School of Medicine, 330 Cedar St, TE 2-230, New Haven, CT 06520 (R.D., J.H.S., J.C., J.F.G.); U/S Imaging and Interventions (UII), Philips Research North America, Cambridge, Mass (M.L.); Center for Interventional Oncology, Interventional Radiology Section, National Institutes of Health, Bethesda, Md (K.V.S., C.G.J., M.R.D., D.L.W., B.J.W.); Biocompatibles UK Ltd, Farnham, Surrey, England (M.R.D., A.L.L., Y.T.); and Philips Research Hamburg, Hamburg, Germany (D.S., M.G.).
David L WoodsFrom the Russell H. Morgan Department of Radiology and Radiological Science, Division of Vascular and Interventional Radiology, Johns Hopkins Hospital, Baltimore, Md (V.T., R.D., J.H.S., Z.W., J.C., N.B., J.F.G.); Department of Radiology, Yale University School of Medicine, 330 Cedar St, TE 2-230, New Haven, CT 06520 (R.D., J.H.S., J.C., J.F.G.); U/S Imaging and Interventions (UII), Philips Research North America, Cambridge, Mass (M.L.); Center for Interventional Oncology, Interventional Radiology Section, National Institutes of Health, Bethesda, Md (K.V.S., C.G.J., M.R.D., D.L.W., B.J.W.); Biocompatibles UK Ltd, Farnham, Surrey, England (M.R.D., A.L.L., Y.T.); and Philips Research Hamburg, Hamburg, Germany (D.S., M.G.).
Andrew L LewisFrom the Russell H. Morgan Department of Radiology and Radiological Science, Division of Vascular and Interventional Radiology, Johns Hopkins Hospital, Baltimore, Md (V.T., R.D., J.H.S., Z.W., J.C., N.B., J.F.G.); Department of Radiology, Yale University School of Medicine, 330 Cedar St, TE 2-230, New Haven, CT 06520 (R.D., J.H.S., J.C., J.F.G.); U/S Imaging and Interventions (UII), Philips Research North America, Cambridge, Mass (M.L.); Center for Interventional Oncology, Interventional Radiology Section, National Institutes of Health, Bethesda, Md (K.V.S., C.G.J., M.R.D., D.L.W., B.J.W.); Biocompatibles UK Ltd, Farnham, Surrey, England (M.R.D., A.L.L., Y.T.); and Philips Research Hamburg, Hamburg, Germany (D.S., M.G.).
Yiqing TangFrom the Russell H. Morgan Department of Radiology and Radiological Science, Division of Vascular and Interventional Radiology, Johns Hopkins Hospital, Baltimore, Md (V.T., R.D., J.H.S., Z.W., J.C., N.B., J.F.G.); Department of Radiology, Yale University School of Medicine, 330 Cedar St, TE 2-230, New Haven, CT 06520 (R.D., J.H.S., J.C., J.F.G.); U/S Imaging and Interventions (UII), Philips Research North America, Cambridge, Mass (M.L.); Center for Interventional Oncology, Interventional Radiology Section, National Institutes of Health, Bethesda, Md (K.V.S., C.G.J., M.R.D., D.L.W., B.J.W.); Biocompatibles UK Ltd, Farnham, Surrey, England (M.R.D., A.L.L., Y.T.); and Philips Research Hamburg, Hamburg, Germany (D.S., M.G.).
Michael GrassFrom the Russell H. Morgan Department of Radiology and Radiological Science, Division of Vascular and Interventional Radiology, Johns Hopkins Hospital, Baltimore, Md (V.T., R.D., J.H.S., Z.W., J.C., N.B., J.F.G.); Department of Radiology, Yale University School of Medicine, 330 Cedar St, TE 2-230, New Haven, CT 06520 (R.D., J.H.S., J.C., J.F.G.); U/S Imaging and Interventions (UII), Philips Research North America, Cambridge, Mass (M.L.); Center for Interventional Oncology, Interventional Radiology Section, National Institutes of Health, Bethesda, Md (K.V.S., C.G.J., M.R.D., D.L.W., B.J.W.); Biocompatibles UK Ltd, Farnham, Surrey, England (M.R.D., A.L.L., Y.T.); and Philips Research Hamburg, Hamburg, Germany (D.S., M.G.).
Bradford J WoodFrom the Russell H. Morgan Department of Radiology and Radiological Science, Division of Vascular and Interventional Radiology, Johns Hopkins Hospital, Baltimore, Md (V.T., R.D., J.H.S., Z.W., J.C., N.B., J.F.G.); Department of Radiology, Yale University School of Medicine, 330 Cedar St, TE 2-230, New Haven, CT 06520 (R.D., J.H.S., J.C., J.F.G.); U/S Imaging and Interventions (UII), Philips Research North America, Cambridge, Mass (M.L.); Center for Interventional Oncology, Interventional Radiology Section, National Institutes of Health, Bethesda, Md (K.V.S., C.G.J., M.R.D., D.L.W., B.J.W.); Biocompatibles UK Ltd, Farnham, Surrey, England (M.R.D., A.L.L., Y.T.); and Philips Research Hamburg, Hamburg, Germany (D.S., M.G.).
Jean-François GeschwindFrom the Russell H. Morgan Department of Radiology and Radiological Science, Division of Vascular and Interventional Radiology, Johns Hopkins Hospital, Baltimore, Md (V.T., R.D., J.H.S., Z.W., J.C., N.B., J.F.G.); Department of Radiology, Yale University School of Medicine, 330 Cedar St, TE 2-230, New Haven, CT 06520 (R.D., J.H.S., J.C., J.F.G.); U/S Imaging and Interventions (UII), Philips Research North America, Cambridge, Mass (M.L.); Center for Interventional Oncology, Interventional Radiology Section, National Institutes of Health, Bethesda, Md (K.V.S., C.G.J., M.R.D., D.L.W., B.J.W.); Biocompatibles UK Ltd, Farnham, Surrey, England (M.R.D., A.L.L., Y.T.); and Philips Research Hamburg, Hamburg, Germany (D.S., M.G.).

Funding

Center for Interventional OncologyZIDBC011242 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WOOD, BRADFORD J · 2009 to 2025
$18.7M
See, Reach, Treat Tumor-Optimized Transarterial Chemoembolization DrugDeliveryR01CA160771 · NCI · YALE UNIVERSITY · PI GESCHWIND, JEAN-FRANCOIS H, LIN, MINGDE · 2011 to 2015
$2.6M
Interventional OncologyZIACL040015 · CLC · CLINICAL CENTER · PI WOOD, BRADFORD · 2009 to 2025
$0k
NCI NIH HHS R01 CA160771
6 · The paper itself

Abstract

Purpose To assess the visibility of radiopaque microspheres during transarterial embolization (TAE) in the VX2 rabbit liver tumor model by using multimodality imaging, including single-snapshot radiography, cone-beam computed tomography (CT), multidetector CT, and micro-CT. Materials and Methods The study was approved by the institutional animal care and use committee. Fifteen VX2-tumor-bearing rabbits were assigned to three groups depending on the type of embolic agent injected: 70-150-μm radiopaque microspheres in saline (radiopaque microsphere group), 70-150-μm radiopaque microspheres in contrast material (radiopaque microsphere plus contrast material group), and 70-150-μm radiolucent microspheres in contrast material (nonradiopaque microsphere plus contrast material group). Rabbits were imaged with single-snapshot radiography, cone-beam CT, and multidetector CT. Three to 5 weeks after sacrifice, excised livers were imaged with micro-CT and histologic analysis was performed. The visibility of the embolic agent was assessed with all modalities before and after embolization by using a qualitative three-point scale score reading study and a quantitative assessment of the signal-to-noise ratio (SNR) change in various regions of interest, including the tumor and its feeding arteries. The Kruskal-Wallis test was used to compare the rabbit characteristics across groups, and the Wilcoxon signed rank test was used to compare SNR measurements before and after embolization. Results Radiopaque microspheres were qualitatively visualized within tumor feeding arteries and targeted tissue with all imaging modalities (P < .05), and their presence was confirmed with histologic examination. SNRs of radiopaque microsphere deposition increased after TAE on multidetector CT, cone-beam CT, and micro-CT images (P < .05). Similar results were obtained when contrast material was added to radiopaque microspheres, except for additional image attenuation due to tumor enhancement. For the group with nonradiopaque microspheres and contrast material, retained tumoral contrast remained qualitatively visible with all modalities except for micro-CT, which demonstrated soluble contrast material washout over time. Conclusion Radiopaque microspheres were visible with all imaging modalities and helped increase conspicuity of the tumor as well as its feeding arteries after TAE in a rabbit VX2 liver tumor model. (©) RSNA, 2015.

Indexed as

Embolization, TherapeuticAnimalsCone-Beam Computed TomographyContrast MediaEthiodized OilLiver Neoplasms, ExperimentalMaleMicrospheresMultidetector Computed TomographyMultimodal ImagingRabbitsContrast MediaEthiodized Oil

Identifiers

PMID26678453
PMCPMC4886703

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.